ETEva Thijssen

Eva Thijssen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eva Thijssen has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preclinical and clinical investigation of VES001, an oral small molecule sortilin receptor inhibitor for the treatment of frontotemporal dementia: a first-in-human randomized placebo-controlled phase 1 trial

    by Louise Klem, Daniel Dumas, Imogen J. Swift, Sofie L. Frandsen, Ditte Nedergaard Mikkelsen, Laerke Fensbaek, Yalçin Yavuz, Okke Merton, Jesminne Castricum, Simone Prichardt, et al.

  • Open Access

    Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients

    by Eva Thijssen, Bert Tuk, Michel Cakici, Veerle van Velze, Erica Klaassen, Frans Merkus, Teus van Laar, Philip Kremer, Geert Jan Groeneveld

    Apomorphine, used to treat OFF episodes in patients with Parkinson's disease (PD), is typically administered via subcutaneous injections. Administration of an oromucosal solution could offer a non‐invasive and user‐friendly alternative. This two‐part clinical study evaluated the safety, tolerability, pharmacokinetics (PK), and dose proportionality of a novel apomorphine hydrochloride oromucosal solution, as well as its relative bioavailability to subcutaneous apomorphine injection and apomorphine sublingual film. In part A of the study, 12 patients with PD received 2 mg oromucosal apomorphine (4% weight/volume) and 2 mg subcutaneous apomorphine in a randomized order, followed by 4 and 8 mg oromucosal apomorphine. In part B of the study, 13 patients with PD received 7 mg oromucosal apomorphine (7% weight/volume) and 30 mg sublingual apomorphine in a randomized order, followed by 14 mg oromucosal apomorphine. Washout between dose administrations in both study parts was at least 2 days. Safety, tolerability, and PK were assessed pre‐ and post‐dose. Both study parts showed that oromucosal apomorphine was generally well‐tolerated. Observed side effects were typical for apomorphine administration and included asymptomatic orthostatic hypotension, yawning, fatigue, and somnolence. Oromucosal apomorphine exposure increased with dose, although less than dose proportional. The mean (SD) maximum exposure reached with 14 mg oromucosal apomorphine was 753.0 (298.6) ng*min/mL (area under the plasma concentration–time curve from zero to infinity) and 8.0 (3.3) ng/mL (maximum plasma concentration). This was comparable to exposure reached after 2 mg subcutaneous apomorphine and approximately half of the exposure observed with 30 mg sublingual apomorphine. In summary, clinically relevant plasma concentrations could be reached in PD patients without tolerability issues.


  • Open Access

    Treatment Detection and Movement Disorder Society‐Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks

    by Ahnjili ZhuParris, Eva Thijssen, Willem O. Elzinga, Soma Makai‐Bölöni, Wessel Kraaij, Geert J. Groeneveld, Robert J. Doll

    The validation of objective and easy‐to‐implement biomarkers that can monitor the effects of fast‐acting drugs among Parkinson's disease (PD) patients would benefit antiparkinsonian drug development. We developed composite biomarkers to detect levodopa/carbidopa effects and to estimate PD symptom severity. For this development, we trained machine learning algorithms to select the optimal combination of finger tapping task features to predict treatment effects and disease severity. Data were collected during a placebo‐controlled, crossover study with 20 PD patients. The alternate index and middle finger tapping (IMFT), alternative index finger tapping (IFT), and thumb–index finger tapping (TIFT) tasks and the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) III were performed during treatment. We trained classification algorithms to select features consisting of the MDS‐UPDRS III item scores; the individual IMFT, IFT, and TIFT; and all three tapping tasks collectively to classify treatment effects. Furthermore, we trained regression algorithms to estimate the MDS‐UPDRS III total score using the tapping task features individually and collectively. The IFT composite biomarker had the best classification performance (83.50% accuracy, 93.95% precision) and outperformed the MDS‐UPDRS III composite biomarker (75.75% accuracy, 73.93% precision). It also achieved the best performance when the MDS‐UPDRS III total score was estimated (mean absolute error: 7.87, Pearson's correlation: 0.69). We demonstrated that the IFT composite biomarker outperformed the combined tapping tasks and the MDS‐UPDRS III composite biomarkers in detecting treatment effects. This provides evidence for adopting the IFT composite biomarker for detecting antiparkinsonian treatment effect in clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    A Placebo‐Controlled Study to Assess the Sensitivity of Finger Tapping to Medication Effects in Parkinson's Disease

    by Eva Thijssen, Soma Makai‐Bölöni, Emilie van Brummelen, Jonas Den Heijer, Yalcin Yavuz, Robert‐Jan Doll, Geert Jan Groeneveld

    Background: Movement Disorder Society–Unified Parkinson's Rating Scale Part III (MDS‐UPDRS III) is the gold standard for assessing medication effects in patients with Parkinson's disease (PD). However, short and rater‐independent measurements would be ideal for future trials.Objectives: To assess the ability of 3 different finger tapping tasks to detect levodopa/carbidopa‐induced changes over time and to determine their correlation and compare their discriminatory power with MDS‐UPDRS III.Methods: This was a randomized, double‐blind, crossover study in 20 patients with PD receiving levodopa/carbidopa and placebo capsules after overnight medication withdrawal. Pre‐ and up to 3.5 hours postdose, MDS‐UPDRS III and tapping tasks were performed. Tasks included 2 touchscreen‐based alternate finger tapping tasks (index finger versus index–middle finger tapping) and a thumb–index finger task using a goniometer.Results: In the alternate index finger tapping task, levodopa/carbidopa compared with placebo resulted in significantly faster (total taps: 12.5 [95% confidence interval, CI, 6.7–18.2]) and less accurate tapping (total spatial error: 240 mm [95% CI, 123–357 mm]) with improved rhythm (intertap interval standard deviation [SD], −16.3% [95% CI, −29.9% to 0.0%]). In the thumb–index finger task, tapping was significantly faster (mean opening velocity, 151 degree/s [64–237 degree/s]), with a higher mean amplitude (8.4 degrees [3.7–13.0 degrees]) and improved rhythm (intertap interval SD, −46.4% [95% CI, −63.7% to −20.9%]). The speed‐related endpoints showed a moderate‐to‐strong correlation with the MDS‐UPDRS III (r = 0.45–0.70). The effect sizes of total taps and spatial error in the alternate index finger tapping task and opening velocity in the thumb–index finger task were comparable with the MDS‐UPDRS III. In contrast, the MDS‐UPDRS III performed better than the alternate index–middle finger task.Conclusion: The alternate index finger and the thumb–index finger tapping tasks provide short, rater‐independent measurements that are sensitive to levodopa/carbidopa effects with a similar effect size as the MDS‐UPDRS III.


  • Open Access

    A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine

    by Hui Jing Yu, Eva Thijssen, Emilie van Brummelen, Johan L. van der Plas, Igor Radanovic, Matthijs Moerland, Eric Hsieh, Geert Jan Groeneveld, Jean‐Cosme Dodart

    Background: α‐Synuclein (αSyn) is believed to play a central role in Parkinson's disease (PD) neuropathology and is considered a target for disease modification. UB‐312 is a synthetic αSyn peptide conjugated to a T helper peptide and is expected to induce antibodies specifically against oligomeric and fibrillar αSyn, making UB‐312 a potential immunotherapeutic for synucleopathies.Objective: To investigate the safety, tolerability, and immunogenicity of UB‐312 vaccination in healthy participants and to determine a safe and immunologically optimal dose for the first‐in‐patient study.Methods: Fifty eligible healthy participants were enrolled in a 44‐week, randomized, placebo‐controlled, double‐blind study. Participants in seven cohorts were randomized to three intramuscular UB‐312 or placebo injections at weeks 1, 5, and 13 (doses ranging between 40 and 2000 μg). Safety and tolerability were assessed by adverse events, clinical laboratory, vital signs, electrocardiograms, and neurological and physical examinations. Immunogenicity was assessed by measuring serum and cerebrospinal fluid (CSF) anti‐αSyn antibody concentrations.Results: Twenty‐three participants received all three vaccinations of UB‐312. Most adverse events were mild, transient, and self‐resolving. Common treatment‐emergent adverse events included headache, nasopharyngitis, vaccination‐site pain, lumbar puncture‐site pain, and fatigue. UB‐312 induced dose‐ and time‐dependent antibody production. Antibodies were detectable in serum and CSF of all participants receiving the 300/300/300 μg UB‐312 dose regimen. The average CSF/serum ratio was 0.2%.Conclusions: UB‐312 was generally safe, well tolerated, and induced anti‐αSyn antibodies in serum and CSF of healthy participants. The 100 and 300 μg doses are selected for further evaluation in participants with PD. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society


  • Open Access

    A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ‐009

    by Eva Thijssen, Jonas Den Heijer, David Puibert, Laurence Moss, Mingzu Lei, David Hasegawa, Kyo Keum, Ken Mochel, Mohammed Ezzeldin Sharaf, Tom Alfredson, et al.

    Background: Inhalation of apomorphine could be a faster‐acting and more user‐friendly alternative to subcutaneous injection for treating off periods in Parkinson's disease (PD).Objective: The aim of this study was to compare the safety and pharmacokinetics of inhaled apomorphine (AZ‐009) with subcutaneous apomorphine (APO‐go PEN) in healthy volunteers (HVs) and to examine the safety, pharmacokinetics, and efficacy of AZ‐009 in patients with PD.Methods: In part A of this study, eight HVs received 1 mg AZ‐009 and 2 mg subcutaneous apomorphine in a randomized crossover manner. In the subsequent single ascending dose parts in HVs (part B, n = 16) and patients with PD (part C, n = 25), participants were randomized to placebo or AZ‐009 up to 4 mg. In patients, after medication withdrawal, Movement Disorder Society‐Unified Parkinson's Disease Rating Scale part III and on/off states were assessed predose and postdose.Results: AZ‐009 was rapidly absorbed with peak plasma concentrations at 2 minutes, as compared to 30 minutes for subcutaneous apomorphine. Adverse events for AZ‐009 were comparable to subcutaneous apomorphine, except for mild and transient throat irritation. Adverse events limited AZ‐009 dose escalation in HVs to 3 mg. Patients tolerated up to 4 mg. In patients with PD, 2, 3, and 4 mg AZ‐009 reduced mean Movement Disorder Society‐Unified Parkinson's Disease Rating Scale part III score (standard deviation) by 10.7 (13.6), 12.8 (7.9), and 10.3 (3.7) points, respectively, compared to 4.8 (4.9) after placebo at 10 minutes postdose. The percentage of patients achieving full on within 45 minutes postdose increased dose dependently: 0% (placebo), 17% (2 mg), 50% (3 mg), and 83% (4 mg).Conclusions: AZ‐009 appears to be a rapid‐acting and reasonably well‐tolerated formulation for treating off periods. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society


  • TGF-β is a potent inducer of Nerve Growth Factor in articular cartilage via the ALK5-Smad2/3 pathway. Potential role in OA related pain?

    by E.N. Blaney Davidson, A.P.M. van Caam, E.L. Vitters, M.B. Bennink, E. Thijssen, W.B. van Den Berg, M.I. Koenders, P.L.E.M. van Lent, F.A.J. van de Loo, P.M. van der Kraan


  • Top Cited Papers
    Open Access

    Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis

    by Eva Thijssen, Arjan van Caam, Peter M. van der Kraan

    OA is a degenerative joint disease characterized by articular cartilage degradation, osteophyte formation, synovitis, and subchondral bone sclerosis. One of OAs main risk factors is obesity. To date, it is not fully understood how obesity results in OA. Historically, this link was ascribed to excessive joint loading as a result of increased body weight. However, the association between obesity and OA in non–weight-bearing joints suggests a more complex aetiology for obesity-induced OA. In the present review, the link between obesity and OA is discussed. First, the historical view of altered joint loading leading to wear and tear of the joint is addressed. Subsequently, the effects of a disturbed lipid metabolism, low-grade inflammation, and adipokines on joint tissues are discussed and linked to OA. Taken together, inflamed adipose tissue and dyslipidaemia play pivotal roles in obesity-induced OA. It becomes increasingly clear that the link between obesity and OA transcends excessive loading.